

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
June 24, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 23, 2014**

**Keryx Biopharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**000-30929**  
**(Commission**

**File Number)**  
**750 Lexington Avenue**

**13-4087132**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

**New York, New York 10022**

**(Address of Principal Executive Offices)**

**(212) 531-5965**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act.
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

The 2014 annual meeting of stockholders of Keryx Biopharmaceuticals, Inc. ( Keryx ) was held on June 23, 2014. The following matters were voted on by the stockholders: the election of directors, the ratification of the appointment of UHY LLP as Keryx 's independent registered public accounting firm for the year ending December 31, 2014, and the advisory vote on the compensation of named executive officers. At the meeting, Ron Bentsur, Kevin J. Cameron, Joseph Feczko, M.D., Wyche Fowler, Jr., Jack Kaye, Daniel Regan, and Michael P. Tarnok were re-elected to the Board.

The vote with respect to each nominee is set forth below:

<b>Nominee</b>	<b>Total Votes For</b>	<b>Total Votes Withheld</b>	<b>Broker Non-Votes</b>
Ron Bentsur	36,690,444	9,553,767	29,180,554
Kevin J. Cameron	45,939,778	304,433	29,180,554
Joseph Feczko, M.D.	45,936,950	307,261	29,180,554
Wyche Fowler, Jr.	45,910,331	333,880	29,180,554
Jack Kaye	45,933,403	310,808	29,180,554
Daniel Regan	45,974,595	269,616	29,180,554
Michael P. Tarnok	45,938,935	305,276	29,180,554

The vote with respect to the ratification of the appointment of UHY LLP as Keryx 's independent registered public accounting firm for the year ending December 31, 2014, is set forth below:

<b>Total Votes For</b>	<b>Total Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
74,437,251	207,723	779,791	0

The vote with respect to the advisory vote on the compensation of Keryx 's named executive officers is set forth below:

<b>Total Votes For</b>	<b>Total Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
44,916,231	1,129,587	198,393	29,180,554

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**  
(Registrant)

Date: June 24, 2014

By: /s/ James F. Oliviero  
James F. Oliviero  
Chief Financial Officer